Literature DB >> 21944287

Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents.

Pamela Kassis1, Joanna Brzeszcz, Valérie Bénéteau, Olivier Lozach, Laurent Meijer, Rémi Le Guével, Christiane Guillouzo, Krzysztof Lewiński, Stéphane Bourg, Lionel Colliandre, Sylvain Routier, Jean-Yves Mérour.   

Abstract

We here report the synthesis and biological evaluation of new 3-[(2-indolyl)]-5-phenyl-3,5-pyridine, 3-[(2-indolyl)]-5-phenyl-2,4-pyridine and 3-[(2-indolyl)]-5-phenyl-2,6-pyrazine derivatives designed as potential CDK inhibitors. Indoles and phenyls were used to generate several substitutions of the pyridine and pyrazine rings. The synthesis included Stille or Suzuki type reactions, which were carried out on the 3,5-dibromopyridine, 2,4-dichloropyridine and 2,6-dichloro-1-4-pyrazine moieties. Cell effects of the V-shaped family were in the micromolar range. Kinase assays were conducted and showed that compound 11 inhibited CDK5 with an inhibitory concentration of 160 nM with a moderate selectivity over GSK3 compared to the reference C which exhibited a slightly lower activity on CDK5 (1.5 μM). Compound 11 was also found to be the most potent compound in the series and was identified as a new lead for DYRK1A inhibitor discovery (IC(50) = 60 nM). Docking studies were carried out in order to investigate the inhibition of DYRK1A.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21944287     DOI: 10.1016/j.ejmech.2011.08.048

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  10 in total

1.  Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors.

Authors:  Julien Debray; Simon Bonte; Olivier Lozach; Laurent Meijer; Martine Demeunynck
Journal:  Mol Divers       Date:  2012-09-19       Impact factor: 2.943

2.  Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Roberto Sanchez; Ethan A Swartz; Andrew F Stewart; Robert J DeVita
Journal:  J Med Chem       Date:  2018-08-21       Impact factor: 7.446

3.  Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic β-cell proliferation activity.

Authors:  Kunal Kumar; Peter Man-Un Ung; Peng Wang; Hui Wang; Hailing Li; Mary K Andrews; Andrew F Stewart; Avner Schlessinger; Robert J DeVita
Journal:  Eur J Med Chem       Date:  2018-08-22       Impact factor: 6.514

4.  Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.

Authors:  Jiansong Fang; Ranyao Yang; Li Gao; Shengqian Yang; Xiaocong Pang; Chao Li; Yangyang He; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2014-12-16       Impact factor: 2.943

Review 5.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

Review 6.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

Review 7.  The azaindole framework in the design of kinase inhibitors.

Authors:  Jean-Yves Mérour; Frédéric Buron; Karen Plé; Pascal Bonnet; Sylvain Routier
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

8.  Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation.

Authors:  Kunal Kumar; Peng Wang; Ethan A Swartz; Susmita Khamrui; Cody Secor; Michael B Lazarus; Roberto Sanchez; Andrew F Stewart; Robert J DeVita
Journal:  Molecules       Date:  2020-04-23       Impact factor: 4.411

9.  Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human β-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor.

Authors:  Kunal Kumar; Peng Wang; Jessica Wilson; Viktor Zlatanic; Cecilia Berrouet; Susmita Khamrui; Cody Secor; Ethan A Swartz; Michael Lazarus; Roberto Sanchez; Andrew F Stewart; Adolfo Garcia-Ocana; Robert J DeVita
Journal:  J Med Chem       Date:  2020-02-19       Impact factor: 7.446

10.  Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.

Authors:  Hye Ree Yoon; Anand Balupuri; Kwang-Eun Choi; Nam Sook Kang
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.